Search results for "Vaporizer"

showing 7 items of 27 documents

The inhalation manager: a new computer-based device to assess inhalation technique and drug delivery to the patient.

2003

The rational choice of an inhalation device is a cornerstone in the effective management of asthma and COPD. In this publication, we describe the development of a new system, the Inhalation Manager, which, for the first time, offers the possibility to assess the entire inhalation maneuver of patients using original devices under everyday conditions. So far the Inhalation Manager allows the measurement of inspiratory maneuvers of patients through placebo inhalation devices of the most common breath-actuated CFC-free inhalers in the market for the three main glucocorticosteroids Budesonide [Turbohaler (TH), dry powder inhaler (DPI)], Beclomethasone dipropionate [Autohaler (AH), breath-actuate…

Pulmonary and Respiratory MedicineBudesonideAdultMaleInhalationAdolescentbusiness.industryInhalerNebulizers and VaporizersBeclometasone dipropionateMiddle AgedMetered-dose inhalerDry-powder inhalerFluticasone propionateDrug Delivery SystemsAnesthesiamedicineHumansPharmacology (medical)FemaleParticle SizebusinessFluticasonemedicine.drugJournal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine
researchProduct

Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions

2008

Patients suffering from cystic fibrosis (CF) often need to inhale multiple doses of different nebulizable drugs per day. Patients attempt to shorten the time consuming administration procedure by mixing drug solutions/suspensions for simultaneous inhalation. The objective of this experimental study was to determine whether mixtures of the nebulizer solution dornase alfa (Pulmozyme) with tobramycin nebulizer solutions (TOBI and GERNEBCIN 80 mg) are physico-chemically compatible. Drug combinations were prepared by mixing the content of one respule Pulmozyme with either one respule TOBI or one ampoule GERNEBCIN 80 mg. Test solutions were stored at room temperature and exposed to light. Dornase…

Pulmonary and Respiratory MedicineChemical PhenomenaCystic FibrosisExcipientAmpouleDrug Incompatibilitychemistry.chemical_compoundAdministration InhalationTobramycinDeoxyribonuclease IHumansMedicinePotencyChromatographyInhalationbusiness.industryNebulizers and VaporizersDornase alfaSodium metabisulfiteAnti-Bacterial AgentsDrug CombinationsPharmaceutical SolutionsNebulizerchemistryAnesthesiaPediatrics Perinatology and Child HealthTobramycinbusinessmedicine.drugPediatric Pulmonology
researchProduct

Physicochemical compatibility and stability of nebulizable drug admixtures containing Dornase alfa and tobramycin.

2012

The objective of this in-vitro study was to determine whether admixtures of the inhalation solutions Pulmozyme(®) (Dornase alfa) and either Bramitob(®) or Tobi(®) (both containing Tobramycin) are physicochemically compatible and to analyze the aerodynamic parameters of these admixtures. After mixing, test solutions were stored at room temperature and under ambient light conditions over a period of 24 h. Tobramycin concentrations were determined by using a fluorescence immunoassay. Stability of dornase alfa was determined by size-exclusion high performance liquid chromatography, ultraviolet spectroscopy, sodium dodecyl sulfate polyacrylamide gel electrophoresis and tentacle strong cation-exc…

Pulmonary and Respiratory MedicineTime FactorsDrug StorageHigh-performance liquid chromatographyDrug Incompatibilitychemistry.chemical_compoundDrug StabilityAdministration InhalationmedicineTobramycinGeometric standard deviationDeoxyribonuclease IPharmacology (medical)Sodium dodecyl sulfateParticle SizeAerosolsChromatographyInhalationNebulizers and VaporizersBiochemistry (medical)Osmolar ConcentrationDornase alfaHydrogen-Ion ConcentrationRecombinant ProteinsAnti-Bacterial AgentsDrug CombinationsPharmaceutical SolutionschemistryCompatibility (mechanics)TobramycinFeasibility StudiesParticle fractionmedicine.drugPulmonary pharmacologytherapeutics
researchProduct

A simple method of bronchoprovocation using a valved holding chamber.

2004

This study was undertaken to ascertain whether the use of a valved holding chamber (VHC) during bronchial provocation testing might increase lung deposition and repeatability of the test relative to the tidal breathing method. The 2-min tidal breathing results were compared to five inhalations from a VHC device in patients using the Pari-provoII nebulizer (MMD = 2.1mkm). Lung and mouth deposition, losses though the exhaled air and losses before aerosol delivery to the patient's mouth were measured in patients using a radiolabeled 99Tc-DTPA solution and gamma camera. The study revealed that lung deposition was 67% with the VHC method, and losses with exhaled air were 29% of the inhaled amoun…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyBronchial Provocation TestsTidal VolumeMedicineHumansPharmacology (medical)In patientRadionuclide ImagingLungAerosolsLungbusiness.industryNebulizers and VaporizersRepeatabilityrespiratory systemHOLDING CHAMBERrespiratory tract diseasesSurgeryAerosolNebulizermedicine.anatomical_structureBronchial provocationTechnetium Tc 99m PentetateRadiopharmaceuticalsbusinessNuclear medicineDeposition (chemistry)Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine
researchProduct

Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?

2015

Inhalation is the preferred route of drug administration in chronic respiratory diseases because it optimises delivery of the active compounds to the targeted site and minimises side effects from systemic distribution. The choice of a device should be made after careful evaluation of the patient's clinical condition (degree of airway obstruction, comorbidities), as well as their ability to coordinate the inhalation manoeuvre and to generate sufficient inspiratory flow. These patient factors must be aligned with the specific advantages and limitations of each inhaler when making this important choice. Finally, adherence to treatment is not the responsibility of the patient alone, but should …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveSocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Anti-asthmatic AgentMedication AdherencePulmonary DiseasePulmonary Disease Chronic ObstructiveSuspensionsAdministration InhalationmedicineCOPDHumansPharmacology (medical)Anti-Asthmatic AgentsMetered Dose InhalersRespiratory systemParticle SizeIntensive care medicineAsthmaAdherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical); Medicine (all)COPDInhalationbusiness.industryMedicine (all)InhalerNebulizers and VaporizersBiochemistry (medical)Adherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)InhalerDry Powder InhalersAirway obstructionmedicine.diseaseAsthmaSolutionsInhalationAdherenceAdministrationAdherence; Asthma; COPD; InhalerbusinessPulmonary pharmacologytherapeutics
researchProduct

Optimization of large-volume injection for the determination of polychlorinated biphenyls in children's fast-food menus by low-resolution mass spectr…

2008

International audience; This study includes the determination of five indicator polychlorinated biphenyls (PCBs) (52, 101, 153, 138, and 180), six non-ortho PCBs (35, 80, 81, 77, 126, and 169), and two mono-ortho PCBs (28 and 118) in fast food for children. A freeze-dried sample of 10 g is extracted by using pressurized n-hexane in two 5 min cycles at 120 degrees C and 100 mbar. Fatty extracts were cleaned up by means of acetonitrile/n-hexane partitioning and gel-permeation chromatography. The fractionation of non-ortho, mono-ortho, and indicator PCBs was made on graphitized carbon solid-phase extraction cartridges by using n-hexane, n-hexane/toluene (99:1, v/v), and toluene as elution solv…

Quality ControlAnalytical chemistryFractionation010501 environmental sciencesTandem mass spectrometryMass spectrometry01 natural sciencesGas Chromatography-Mass SpectrometryMass Spectrometry[CHIM.ANAL]Chemical Sciences/Analytical chemistryTandem Mass SpectrometryHumansPCBs0105 earth and related environmental sciencesDetection limitChromatographyChemistryElution010401 analytical chemistryReproducibility of ResultsGeneral ChemistryRepeatabilityPolychlorinated Biphenyls0104 chemical sciencesChild PreschoolGas chromatographyVaporizerGeneral Agricultural and Biological SciencesFood AnalysisJournal of agricultural and food chemistry
researchProduct

Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage.

2014

International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studi…

medicine.medical_specialtyCombination therapyAsthma exacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerAsthma controlFluticasone propionate/formoterolForced Expiratory VolumeFormoterol FumarateInternal MedicineMedicineHumansAnti-Asthmatic AgentsAsthma exacerbationsParticle SizeIntensive care medicineAsthmaFluticasonebusiness.industryInhalerNebulizers and VaporizersFixed-combination therapyAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhaler; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; Ethanolamines; Fluticasone; Forced Expiratory Volume; Formoterol Fumarate; Humans; Nebulizers and Vaporizers; Particle Size; Quality of Life; Treatment Outcomemedicine.diseaseSingle-aerosol inhalerAsthmaBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilityAsthma control Asthma exacerbations Fixed-combination therapy Fluticasone propionate/formoterol Single-aerosol inhalerEthanolaminesAnesthesiaAsthma exacerbations; Asthma control; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerQuality of LifeFluticasoneFormoterol FumarateFormoterolbusinessmedicine.drugEuropean journal of internal medicine
researchProduct